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Recently, the p53 homolog p63 has been implicated
in sustaining the epidermal stem cell population. The
p63 gene encodes six major products with transactiv-
ating or dominant-negative properties. The expres-
sion pattern of these isoforms in keratinocytes was
investigated here. Northern blot, ribonuclease pro-
tection assay, reverse transcription±polymerase chain
reaction, and western blot techniques sensitive for all
six p63 isotypes veri®ed the predominant expression
of the truncated and potentially dominant-negative
isotype DNp63a in human keratinocytes. The expres-
sion of this isoform is downregulated when pro-
liferating human primary keratinocytes begin to
differentiate after growth factor withdrawal. The
onset of differentiation does not change the ratio of
two other weakly expressed isotypes DNp63g and
TAp63a relative to DNp63a. Treatment of primary
human keratinocytes with all-trans retinoic acid does
not alter the expression pattern of p63 isotypes but
prevents its downregulation as observed in control
cell cultures. These data suggest that p63 expression
in human keratinocytes is affected by all-trans reti-
noic acid and this in¯uence might contribute to the
®ne tuned keratinocyte proliferation and differenti-
ation equilibrium in the mammalian epidermis. Key
words: involucrin/p53 protein family/p63 splice variants. J
Invest Dermatol 118:133±138, 2002
p63 shows remarkable structural homology to the relatedprotein p73 and the tumor suppressor p53 (Yang andMcKeon, 2000; Strano et al, 2001). Whereas only a single
isoform of p53 is known, multiple p63 and p73 transcripts
are observed. At least two promoters exist in the p63
gene, yielding transactivating (TA, transactivation domain) as well
as transactivating (DN, n-terminally truncated) isotypes. A
conserved DNA binding domain and a basic tetramerization
domain are present in all p63 isotypes. In conjunction with the
three different carboxy-termini, a, b, and g, six major p63 isoforms
are possible. For clari®cation, a full length cDNA or protein is
described by its speci®c start point (TA or DN) followed by the
gene name (p63) and the speci®c endpoint (a, b, or g). The gene
name followed by one speci®c isoform attribute refers exclusively
to this isoform irrespective of other possible isoforms at the
alternative end. TAp63g resembles most p53, whereas the p63a and
p63b splice variants extend the p63 protein sequence considerably.
The full length p63a protein contains a sterile a motif-like
sequence and a negatively charged C-terminus. As a result of exon
13 deletion, only the N-terminal part of the sterile a motif-protein
domain is expressed in the p63b isoform. All p63 isoforms
potentially bind to p53 responsive promoter elements but only
TAp63g and TAp63b transactivate reporter genes at levels
comparable with wild-type p53 (Celli et al, 1999). TAp63a,
possibly as consequence of an inhibitory effect of the C-terminus,
and all p63DN isoforms completely lack this ability.
Basal keratinocytes in normal skin express detectable levels of
DNp63a and its expression is associated with the proliferative
potential in normal and neoplastic human keratinocytes (Parsa et al,
1999). DNp63a overexpression in mouse epidermis using the
loricrin promoter results neither in an overt phenotype nor in an
altered proliferation rate (Liefer et al, 2000).
Vitamin A and its major biologically active form all-trans retinoic
acid have been appreciated as critical regulators of growth and
differentiation in the developing and adult skin (Fisher and
Voorhees, 1996). Proliferating keratinocytes in the basal layer of
the skin leave the cell cycle and move on to an early phase of
differentiation. Subsequently, keratinocytes form cross-linked
envelopes in a late stage of differentiation (Green and Watt,
1982). Involucrin is a precursor protein of the corni®ed envelope
and a marker for early keratinocyte differentiation.
In vitro, addition of retinoic acid to primary human keratinocyte
cell cultures, which start to differentiate after growth factor
withdrawal, ef®ciently retards corni®ed envelope formation and
marginally stimulates proliferation. During the ®rst 14 d of retinoic
acid supplementation the amount of involucrin is comparably high
in treated and untreated keratinocyte cultures (Cline and Rice,
1983), whereas the number of corni®ed envelopes is drastically
reduced.
In vivo, retinoids do not suppress keratinocyte terminal differ-
entiation but stimulate keratinocyte proliferation. Therefore,
0022-202X/01/$15.00 ´ Copyright # 2002 by The Society for Investigative Dermatology, Inc.
133
Manuscript received July 19, 2001; revised September 20, 2001;
accepted for publication October 16, 2001.
Reprint requests to: Hartwig Schmale, Institut fuÈr Zellbiochemie und
Klinische Neurobiologie, UniversitaÈtsklinikum Hamburg-Eppendorf,
Martinistrasse 52, 20246 Hamburg, Germany. Email: schmale@uke.uni-
hamburg.de
Abbreviations: b, bases; BPE, bovine pituitary extract; HGPRT,
hypoxanthine guanine phosphoribosyl transferase; KGM, keratinocyte
growth medium; DN, N-terminally truncated; RPA, ribonuclease protec-
tion assay; TA, transactivation.
retinoic acid is thought to modify the ®nely tuned balance between
these two cellular processes.
Because of the ability of retinoids to modify keratinocyte
differentiation, we investigated p63 splice variant expression in
human primary keratinocytes. As an experimental approach, we
used cell cultures cultivated under differentiation promoting
conditions (Poumay et al, 1999) to study the development of p63
expression in detail over time during terminal differentiation.
MATERIALS AND METHODS
Cell culture Normal human primary keratinocytes (Clonetics,
CellSystems, St. Katharinen, Germany) were cultivated on cell culture
plates (Nalge Nunc Int., Rochester, NY) at 37°C and 5% CO2. For all
assays, keratinocytes in the third or fourth passage were used and media
were renewed every second day. All experiments were repeated three
times with different healthy donors for primary keratinocytes.
A simple change of culture media from proliferation- to differenti-
ation-promoting cell culture conditions started the differentiation experi-
ments. In detail, the proliferation-promoting keratinocyte growth
medium (KGM-2, Clonetics) included bovine pituitary extract, insulin,
transferrin, epinephrine, epidermal growth factor, and 0.15 mM CaCl2
according to manufacturer's instructions. These supplements were omit-
ted in the differentiation promoting keratinocyte basal medium-2
(Clonetics), whereas the calcium concentration was kept.
Keratinocytes at 50% cell density were washed twice with keratinocyte
basal medium-2, cells were subsequently refed every second day with
keratinocyte basal medium-2 and grown under differentiation promoting
conditions for 11 d at 37°C and 5% CO2.
For retinoic acid treatment, keratinocytes grown to 50% cell density
were washed twice with KGM-2 medium without bovine pituitary
extract (KGM-2-BPE). Cells were cultivated for 10 further days at 37°C
and 5% CO2 in KGM-2-BPE supplemented with 0.1 mM all-trans
retinoic acid (Sigma, Deisenhofen, Germany). Retinoic acid stock
solutions were prepared in dimethyl sulfoxide (Sigma) and control cells
were grown in KGM-2-BPE, including 0.01% dimethyl sulfoxide for the
same time span.
HaCaT cells kindly provided by Dr. N. Fusenig (Boukamp et al,
1988) and HEK293 cells (Graham et al, 1977) were cultivated in DMEM
(Gibco, Eggenstein, Germany), including 10% fetal bovine serum
(Gibco).
Preparation of human epidermis Skin from circumcisions (kindly
provided by the children's hospital, UniversitaÈtsklinikum-Hamburg
Eppendorf) was washed three times in wash buffer (1 3 phosphate-
buffered saline without calcium and magnesium supplemented with
0.5 mg per ml gentamicin (Gibco)); 0.25 cm2 skin segments were dispase
I digested (2.4 U per ml dispase I in wash buffer) overnight at 4°C.
Using forceps, the epidermis was carefully separated from the dermis and
stored at ±70°C.
RNA preparation Human tissues used for RNA isolation were
removed at autopsy and stored at ±70°C. For RNA preparation from
human cell culture cells, any liquid was removed from the Petri dishes,
they were quickly cooled on dry ice and subsequently stored at ±70°C.
Total RNA was isolated using RNAclean (Hybaid-AGS, Heidelberg,
Germany) according to the manufacturer's instructions.
Northern blot, ribonuclease protection assay (RPA), and reverse
transcription±polymerase chain reaction (reverse transcription±
PCR) The northern blot technique was employed for quantitative
detection of human mRNA with the following a-32P-deoxycytidine
triphosphate labeled cDNA fragments (Amersham, Freiburg, Germany).
Labeling was carried out with the Prime it II Random Primer Labeling
Kit (Stratagene, La Jolla, CA), cDNA fragments were puri®ed by gel
®ltration through Nuctrap Push columns (Stratagene) and quanti®ed in a
Wallac 1409 scintillation counter (Wallac, Freiburg, Germany). The
p63core probe of 232 bp length (nt 964±1195; GB: AF075430) was used
to detect all human p63 mRNA splice variants. Involucrin expression
was analyzed by a 1647 bp long involucrin cDNA fragment (nt 183±
1830; GB: M13902). The b-actin mRNA was identi®ed with a 377 bp
long b-actin probe (nt 1418±2234, excluding intron C; GB: M10277).
Glyoxal denatured total RNA (15 mg) was separated in a phosphate-
buffered 1.2% agarose gel. The RNA was transferred overnight on to a
Hybond-N nylon membrane (Amersham) according to the
manufacturer's instructions. The RNA molecules were heat cross-linked
to the nylon membrane (80°C, 2 h) and prehybridization was performed
at 42°C in ULTRAhyb buffer (Ambion, Austin, TX) for 2 h. The
denatured radioactive labeled cDNA probe (95°C, 10 min, followed by
4°C, 5 min) was added to ULTRAhyb buffer (preheated to 68°C) to a
®nal concentration of 2 3 107 cpm per ml. The northern blot was
incubated overnight at 42°C in hybridization buffer. After washing twice
for 15 min at 42°C in 2 3 sodium citrate/chloride buffer/0.1% (wt/vol)
sodium dodecyl sulfate (SDS) followed by 15 min at 42°C in
0.2 3 sodium citrate/chloride buffer/0.1% (wt/vol) SDS blots were
analyzed with the phosphoimager system Fuji BAS-1800II reader and the
AIDA software package (Raytest, Straubenhardt, Germany). The
northern blot was stripped in 0.1 3 sodium citrate/chloride buffer/50%
formamide (75°C, 1 h) and rehybridized with another radioactively
labeled probe as described. Because of mRNA length and signal strength
RNA were detected in the following order: p63, involucrin and b-actin.
For RPA, contaminating DNA in tissue and cell culture total RNA
preparations was removed by DNaseI digestion (1 U per mg RNA,
15 min at 37°C in 1 3 transcription buffer; Roche, Mannheim,
Germany). A total of 15 mg tissue RNA or 10 mg cell culture RNA per
assay was incubated with 5 3 105 cpm a-32P-uridine triphosphate
(Amersham) labeled probe at 42°C overnight in hybridization buffer
(RPA-III-Kit, Ambion). A b-actin or hypoxanthine guanine phosphor-
ibosyl transferase (HGPRT) speci®c probe (5 3 104 cpm per total RNA
probe) was included as internal control. Riboprobes have the suf®x ``-p''
and were generated by in vitro transcription of 1 mg linearized plasmid
DNA with T7 RNA polymerase (Roche). 5¢p63-p of 296 b length was
used to hybridize to 236 b of the human p63TA mRNA (nt 166±401;
GB: AF075430). Owing to the probe design (Fig 1), simultaneous
detection of p63DN was possible as a 195 b long protected complemen-
tary RNA fragment. The p63a and p63g splice variants were detected
by the 3¢p63-p of 262 b length, resulting in protected complementary
RNA fragments of 164 b and 201 b (nt 904±1104; GB: AF075429),
respectively. A 335 b long HGPRT RNA fragment (nt 2324±568; GB:
NM_000194) was protected by the 421 b long transcript named
HGPRT-p. Act-p of 160 b length hybridized to 125 b of the human
b-actin mRNA (nt 821±945; GB X00351; pTRI-b-actin-125-Human
Anti-sense Control Template plasmid; Ambion; T3 RNA polymerase
(Roche) transcript). For p63 5¢-end and 3¢-end detection, RNase
treatment was carried out for 40 min at 37°C with RNaseA/T1 (1:100
dilution) and RNaseT1 (1:50 dilution; RPA-III-Kit; Ambion), respect-
ively. After separation of complementary RNA fragments in a 8%
polyacrylamide gel, radioactive bands were analyzed on the dried gel
with the phosphoimager system Fuji BAS-1800II reader and the AIDA
software package (Raytest).
For reverse transcription±PCR, 2 mg of total RNA was reverse
transcribed using Superscript II reverse transcriptase (Gibco) and random
hexamer primers (Amersham). A PCR approach with a p63 5¢-end
forward and 3¢-end reverse oligonucleotide identi®ed the expressed p63
5¢/3¢-end combination. Speci®c p63 cDNA sequences were analyzed
with the forward and reverse oligonucleotides listed in Table I. Primers
were selected using the Lasergene program package (DNASTAR,
Madison, WI). The HGPRT and one speci®c p63 splice variant cDNA
were ampli®ed from 1/20 of the reverse transcribed total RNA with the
ELONGASE Enzyme Mix (BRL Life Technologies). PCR was per-
formed in 35 cycles (94°C for 2 min for the initial denaturation, 94°C
for 30 s and 55°C for 30 s and 68°C for 2 min 30 s for each cycle and
68°C for 10 min for the ®nal elongation). PCR fragments were
visualized with ethidium bromide after separation of equal volumes of
each reaction on a 1.2% (wt/vol) agarose gel.
Western blot For SDS gel electrophoresis, cultured cells were lyzed in
1 3 gel-loading buffer (2% SDS/60 mM Tris (pH 7.5)/100 mM
dithiothreitol). The proteins were heat denatured (96°C, 5 min) and
Figure 1. Schematic of the main p63 mRNA isotypes.
Untranslated mRNA sequence is indicated in black. Gray areas highlight
the conserved TA domain, the DNA binding domain (DBD), the
oligomerization domain (OD) and the sterile a motif domain (SAM).
Positions of the complementary RPA probes 5¢p63-p and 3¢p63-p are
indicated.
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after determination of protein concentration 10 mg per mm2 protein was
separated in a 8% SDS±acrylamide gel and blotted on to Immobilon-P
(Millipore, Eschborn, Germany) according to standard procedures.
Primary antibodies were diluted 1:200 for p63 monoclonal antibody 4A4
(Santa Cruz Biotechnology, Santa Cruz, CA), 1:10,000 for involucrin
monoclonal antibody SY5 (Sigma) and 1 : 40,000 for b-actin
monoclonal antibody 15 (Sigma) in blocking buffer (5% dried skimmed
milk/1 3 Tris-buffered saline/0.2% Nonidet P-40). After incubation
with primary antibody (4°C, o/n), blots were washed ®ve times in
1 3 Tris-buffered saline (room temperature, 10 min) and bound
antibodies were detected with horseradish coupled anti-mouse IgG
(dilution 1 : 2500 in blocking buffer, room temperature, 2 h, ECL-
System, Amersham). The ®nal washing was performed as described and
the horseradish peroxidase activity was detected with the SuperSignal
Substrate (Pierce, Rockford, IL), measured with a Lumi-Imager (Roche)
and quanti®ed with the provided software.
RESULTS
Tissue distribution of p63 splice variants p63 expression was
analyzed by RPA in different human tissues and cell lines with
splice variant speci®c probes (Fig 1). The RPA probe 5¢p63-p was
used to detect p63TA (236 b). Protected complementary RNA
fragments 41 b shorter than the expected p63TA fragment
indicated p63DN (195 b) expression. In analogy, 3¢p63-p was
designed for the two alternative p63 3¢-ends, p63a and p63g.
3¢p63-p protected 164 b common to all p63 splice variants and
therefore indicated p63a and p63b expression. We did not
differentiate between these isoforms because p63b is a minor
transcript showing the same expression pro®le as p63a (Bamberger
and Schmale, 2001). Additional 37 b are included in the case of
p63g (201 b) expression. HGPRT expression was monitored as
positive control in all tissues and cell lines.
As indicated by RPA analysis, the existence of all four
investigated p63 splice variants DN, TA, a, and g was proven in
human tongue consisting of multiple tissues such as epithelium,
tongue muscle, and salivary glands (Fig 2A, B). RPA detected
weakly but consistently the existence of TAp63g mRNA in human
skeletal muscle tissue. Very weak expression of p63DN was also
found in skeletal muscle. The same RPA experiments suggest
DNp63a expression in human placenta. In a spontaneously
transformed human epithelial cell line from adult skin termed
HaCaT (Boukamp et al, 1988) DNp63a was detectable in 25%
higher levels than in proliferating primary human keratinocytes
when normalized to HGPRT expression. As a negative control, the
human embryonic kidney cell line HEK293 (Graham et al, 1977)
was included in a 5-fold excess of total RNA. Neither 5¢p63-p nor
3¢p63-p detected any p63 expression.
p63 expression in human keratinocytes The described RPA
experiments demonstrated the tissue distribution of individual p63
splice modules. Proliferating human primary keratinocytes in cell
culture expressed DNp63a as the major splice variant. In order to
investigate the p63 expression in human keratinocytes in more
detail, speci®c PCR primers were used to amplify the entire coding
region. In normal human epidermal total RNA, DNp63a was
veri®ed as the major p63 splice variant (Fig 3A). In addition, very
weak expression of TAp63a and DNp63g was detected. Southern
blot analysis of 1/50 of the reverse transcription±PCR reaction
volume veri®ed the TA1p63a and TA2p63a expression in the
human epithelium (not shown). TA1 and TA2 represent two
alternative 5¢-ends of the TA containing isoforms (Bamberger and
Schmale, 2001). Reverse transcription±PCR experiments did not
Table I. Reverse transcription±PCR ampli®cation primers used for detection of human HGPRT and p63 splice variantsa
Identi®cation Forward primer Reverse primer Size (bp) Position (nt) GB
TAp63a 5¢-gcc cat tga ctt gaa ctt tgt g-3¢ 5¢-gtc tgg cgg agg gtg aat -3¢ 1727 92-1818 AF075430
TA1p63a 5¢-aga gag ggg gaa gaa caa cag-3¢ 5¢-gtc tgg cgg agg gtg aat -3¢ 1924 42-1965 (AF075430)
TA2p63a 5¢-ttt gca aat atg tat gaa gga gag aag-3¢ 5¢-gtc tgg cgg agg gtg aat -3¢ 2111 76-2186 (F075430)
DNp63a 5¢-ggg gtt ggc aaa atc ctg-3¢ 5¢-gtc tgg cgg agg gtg aat -3¢ 1727 55-1781 (F075431)
TAp63g 5¢-gcc cat tga ctt gaa ctt tgt g-3¢ 5¢-gcc cag cag tac act tga ca-3¢ 1807 92-1898 AF075428
TA1p63g 5¢-aga gag ggg gaa gaa caa cag-3¢ 5¢-gcc cag cag tac act tga ca-3¢ 2003 42-2044 (F075428)
TA2p63g 5¢-ttt gca aat atg tat gaa gga gag aag-3¢ 5¢-gcc cag cag tac act tga ca-3¢ 2190 76-2265 (F075428)
DNp63g 5¢-ggg gtt ggc aaa atc ctg-3¢ 5¢-gcc cag cag tac act tga ca-3¢ 1806 55-1860 (F075429)
HGPRT 5¢-cgt cgt gat tag tga tga tga-3¢ 5¢-ttc aaa tcc aac aaa gtc tgg c-3¢ 526 106-631 NM00194
aNumbers given in brackets indicate that the ampli®ed PCR product is identical to a part of the Gene Bank cDNA entry.
Figure 2. Expression of p63 splice variants in different human
tissues and cell lines. The RPA identi®ed 5¢-end (A) and 3¢-end (B)
splice variants of p63 in the human tissues tongue, muscle, and placenta,
and in the cell lines HaCaT and HEK and in primary keratinocyte cell
culture. The quantity of RNA was monitored by HGPRT detection.
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show comparable expression intensity of TAp63a in normal
human primary keratinocytes, whereas DNp63a and DNp63g
expression was still observed (Fig 3B). Nonquantitative reverse
transcription±PCR results suggest a ratio of DNp63b to DNp63a of
1:10. HGPRT ampli®cation was included in the same reverse
transcription±PCR reaction as positive control in both experi-
ments. In order to demonstrate successful PCR of the p63 variants,
about 10,000 cDNA copies of every splice variant served as the
template in a positive PCR reaction (Fig 3C). Ampli®cation failed
in a negative control reaction (not shown).
p63 expression during keratinocyte differentiation One
major question concerning p63 in skin is its change in expression
during early differentiation of epidermal keratinocytes. We followed
p63 expression in keratinocytes grown under differentiation
promoting conditions with emphasis on the quantity and the
pattern of the observed p63 splice variants. Northern blot analysis
indicated a 5-fold reduction in the DNp63a mRNA level after 11 d
of culture under differentiation promoting conditions when
normalized to b-actin (Fig 4A). The process of ongoing
differentiation of the keratinocytes was shown by the 4-fold
induction of the involucrin mRNA expression, used as a positive
marker for early differentiation. The observed reduction of DNp63a
mRNA results in a 50-fold decrease in protein as shown by western
blot analysis (Fig 4B). In addition, RPA experiments indicated no
upregulation of any of the two other p63 splice variants TA and g at
the time points investigated (Fig 4C, D). A second protein detected
by the monoclonal 4A4 antibody, which migrates faster than the
61 kDa marker protein, might result from the translation of DNp63g
mRNA because very weak expression of the g isoform was also
detected with RPA (Fig 4D). The change in p63 mRNA
expression relative to b-actin expression was quanti®ed in three
independent experiments using RPA (Fig 4E).
The in¯uence of retinoic acid on p63 expression Addition of
retinoic acid to the cell culture medium prevents terminal
differentiation of human primary keratinocytes. When compared
with control cell cultures, p63 mRNA and protein levels remained
high in keratinocytes after 10 d of treatment with 0.1 mM all-trans
Figure 4. DNp63a expression drops during differentiation
promoting cultivation of human primary keratinocytes. The
involucrin, p63 and b-actin mRNA were detected in a northern blot
assay (A). A western blot assay veri®ed the change of p63 protein (B). In
addition, RPA determined the splice variant expression of the p63 5¢-
end (C) and 3¢-end (D). The p63 mRNA expression relative to b-actin
was quanti®ed in three independent experiments (E). Error bars: 6 SD.
Figure 3. DNp63a is the major p63 splice variant expressed in
keratinocytes. Different reverse and forward primer combinations were
used in a reverse transcription±PCR experiment with epidermis RNA
(A) and human primary keratinocyte RNA (B). Copies (1 3 104) of
each cDNA splice variant were used as a template for a positive control
PCR ampli®cation (C).
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retinoic acid (Fig 5). Northern blot analysis (Fig 5A) and western
blot analysis (Fig 5B) indicated high expression of both DNp63a
mRNA and protein. RPA investigations veri®ed these results and
further indicated unchanged expression of the two other p63 splice
variants TA and g (Fig 5C, D). Upregulation of involucrin mRNA
and protein was not in¯uenced by retinoic acid (Green and Watt,
1982). The corni®ed envelope assay (Rice and Green, 1979)
indicated incomplete differentiation of retinoic acid treated
keratinocytes as expected (not shown). The expression of
DNp63a in the presence of retinoic acid was constant when
studied at different time points (Fig 5E). In the keratinocyte
control culture DNp63a was downregulated during the process of
differentiation.
DISCUSSION
Expression of a predominant p63 splice variant might be charac-
teristic for a speci®c cell type. In a proliferating keratinocyte
primary cell culture DNp63a is the major isoform found. In
contrast, TAp63g is the isoform predominantly observed in skeletal
muscle. Different tissue components might contribute to the
detection of all major p63 isoforms in the human tongue; however,
the p63 positive cell types in tongue and placenta were not
determined.
Very low expression of TAp63a was observed in normal human
epidermis. Nonquantitative reverse transcription±PCR results
suggest a reduction in TAp63a expression in keratinocytes upon
in vitro cultivation. Interestingly, TAp63a was detected in HaCaT
cells on protein level (Hall et al, 2000) and in SCC25 cells by
reverse transcription±PCR (Nylander et al, 2000). Expression of
TAp63a is the major difference between epidermis and cultured
epidermal keratinocytes. Although contamination of the human
epidermis with another cell type expressing this p63 isoform cannot
be excluded, these data might imply that TAp63a is the critical
splice variant for the long-term survival of keratinocytes.
Alternatively, the existence of both minor expressed splice variants,
TAp63a and DNp63g, might be explained by leaky transcription
and accidental splicing events.
In the cell culture model used here, keratinocytes began to
differentiate and started to express the early differentiation marker
involucrin. We showed a reduction in DNp63a expression in
primary human keratinocyte cell culture when cells escaped from
the cell cycle and started to differentiate. In situ hybridization and
immunohistochemistry revealed high p63 expression only in the
basal layer, the proliferative compartment of the skin (Parsa et al,
1999). This expression pro®le correlates with the high p63
expression observed in the proliferating keratinocyte cell culture
and subsequent downregulation during differentiation. The change
in DNp63a expression is in agreement with the previously reported
cell size dependent expression of DNp63a (Parsa et al, 1999). Parsa
et al (1999) found that small keratinocytes with high colony
forming potential expressed high amounts of DNp63a, whereas
large differentiated keratinocytes showed only marginal expression.
In accordance with our results, normal human epidermal
keratinocytes induced to differentiate in vitro by high calcium
exposure downregulated all p63 isoforms (De Laurenzi et al, 2000).
Results obtained by different experimental paradigms ± the p63
downregulation after calcium induced differentiation (De Laurenzi
et al, 2000), the cell size dependent expression observed by Parsa
et al (1999) and the differentiation time dependent expression
Figure 5. Retinoic acid blocks the DNp63a
reduction observed during differentiation of
human primary keratinocytes. After 10 d
exposure to 0.1 mM retinoic acid, northern blot
(A) and western blot (B) assays indicated
continuous DNp63a expression in comparison
with untreated keratinocytes. The splice variant
expression was investigated with RPA for
different p63 5¢-ends (C) and 3¢-ends (D). The
development of DNp63a expression during
cultivation in control and retinoic acid treated
human primary keratinocytes was monitored on
protein level using the western blot technique (E).
Phase-contrast photographs indicate the morpho-
logic changes of human primary keratinocytes
after 11 d of culture with or without retinoic acid
(F). Scale bar: 50 mm.
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described here ± argue for high DNp63a levels in proliferating
keratinocytes and a downregulation during differentiation. No
change in the relative p63 splice variant pattern was observed at the
investigated time points. Whether the p63 expression changes its
pattern in keratinocytes in the early response phase to growth factor
withdrawal was not investigated.
Retinoic acid added to a keratinocyte cell culture is known to
inhibit the expression of the differentiated phenotype (Fisher and
Voorhees, 1996). Retinoids allow keratinocytes to proceed
through the early steps of differentiation but block the subsequent
corni®ed envelope formation (Green and Watt, 1982). In vivo,
retinoic acid stimulates in the skin the division of the basal
keratinocytes that migrate upward and differentiate (Fisher et al,
1991). Sustained expression of DNp63a in retinoic acid treated
keratinocytes argues for this p63 isoform as a marker for the
keratinocyte proliferation capacity. In addition, other signals
provided in the basal compartment of normal human epidermis
may be needed for keratinocytes in order to proceed through the
cell cycle.
Is downregulation of DNp63a essential for the onset of
differentiation or rather required to allow other processes that are
speci®c for the differentiated phenotype in suprabasal layers of the
epidermis? Transgenic mice overexpressing DNp63a in the skin
under the control of the basal loricrin promoter show unaltered
proliferation and differentiation of keratinocytes (Liefer et al, 2000).
This ®nding and our data suggest that DNp63a downregulation is
not the driving force for differentiation. Absence of the dominant-
negative DNp63a isoform may release speci®c DNA-binding sites
in responsive genes and allow transcriptional activity of p53 and
p73, the other members of the p53 family.
Despite a decrease in p53 mRNA and protein in human
keratinocytes during differentiation, p53-mediated transcription
activity increases (Weinberg et al, 1995). The downregulation of
the dominant negative DNp63a isoform might explain the
observed increase of p53 activity because both proteins may
compete for the same responsive elements in target gene promoters.
Recently it has been shown that downregulation of p63 is required
for epidermal Ultraviolet B induced p53-dependent apoptosis
(Liefer et al, 2000). Along these lines, the transcriptionally active
isoform of p73, TAp73d, is induced in keratinocytes exposed to
high calcium, whereas the expression of DNp63a is decreased.
TAp73d was reported to be effective in inducing transactivation of
the epidermal differentiation markers, involucrin and loricrin (De
Laurenzi et al, 2000). p53- and p73-null mice, however, exhibit
histologically normal skin (Yang et al, 2000) suggesting a highly
redundant and complex regulatory protein network for keratino-
cyte differentiation.
Vitamin A de®ciency and loss of p63 result in malformation of
distal limb structures. Mice without a functional p63 gene show
major defects in their limb, craniofacial, and epithelial development
(Mills et al, 1999; Yang et al, 1999). Their hindlimbs are absent and
the forelimbs are truncated because the apical ectodermal ridge, an
epithelium essential for limb development, is not maintained.
Interestingly, vitamin A de®ciency during early mammalian
development results in malformations that include cleft face, palate,
and lip, and abnormalities of the forelimbs (Morriss-Kay and Ward,
1999). A similar phenotype is caused by heterozygous germline
mutations in p63 observed in patients who exhibit a syndrome of
ectrodactyly, ectodermal dysplasia and cleft lip with or without cleft
palate (Celli et al, 1999).
Hence p63 expression maintained by retinoic acid seems to be
necessary for normal limb development.
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keratinocyte cell culture handling and of Heidje Christiansen in molecular biology
techniques is gratefully acknowledged. The data presented here form part of a Ph.D.
thesis (CB).
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